Cargando…

Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV

Metabolic risk factors and nonalcoholic fatty liver disease (NAFLD) in people with HIV (PWH) have been increasing. Patients exhibiting the inflammatory subtype nonalcoholic steatohepatitis (NASH) are at increased risk of liver-related complications. Therefore, the aim was to investigate the prevalen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michel, Maurice, Labenz, Christian, Wahl, Alisha, Anders, Malena, Armandi, Angelo, Huber, Yvonne, Galle, Peter R., Sprinzl, Martin, Schattenberg, Jörn M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451864/ https://www.ncbi.nlm.nih.gov/pubmed/35849074 http://dx.doi.org/10.1097/QAD.0000000000003312

Ejemplares similares

Significant liver fibrosis is a predictor of poor health-related quality of life in people living with HIV
por: Michel, Maurice, et al.
Publicado: (2022)

Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV
por: Michel, Maurice, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease in people living with HIV
por: Michel, Maurice, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression
por: Labenz, Christian, et al.
Publicado: (2020)

Impact of thyroid disorders on the incidence of non‐alcoholic fatty liver disease in Germany
por: Labenz, Christian, et al.
Publicado: (2021)

Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany
por: Labenz, Christian, et al.
Publicado: (2020)

Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol
por: Labenz, Christian, et al.
Publicado: (2019)

Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Nier, Anika, et al.
Publicado: (2020)

Health-related quality of life in patients with autoimmune hepatitis
por: Michel, Maurice, et al.
Publicado: (2021)

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies
por: Labenz, Christian, et al.
Publicado: (2020)

Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches
por: Armandi, Angelo, et al.
Publicado: (2021)

Clinical Frailty Scale for risk stratification in patients with SARS-CoV-2 infection
por: Labenz, Christian, et al.
Publicado: (2020)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis
por: Chen, Hui, et al.
Publicado: (2022)

Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study
por: Pfirrmann, Daniel, et al.
Publicado: (2019)

Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis
por: Docherty, Matt, et al.
Publicado: (2021)

Intragastric Balloons: An Emerging Therapy for Nonalcoholic Steatohepatitis and Fibrosis?
por: Jirapinyo, Pichamol, et al.
Publicado: (2019)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

A simple method for inducing nonalcoholic steatohepatitis with fibrosis
por: Yahaghi, Leyla, et al.
Publicado: (2019)

Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

Portal vein thrombosis is associated with an increased risk of bone fractures
por: Gairing, Simon Johannes, et al.
Publicado: (2022)

Burden of depression and anxiety disorders per disease codes in patients with lymphoma in Germany
por: Tilch, Marie-Kristin, et al.
Publicado: (2021)

Portal Vein Thrombosis Is Associated with an Increased Incidence of Depression and Anxiety Disorders
por: Gairing, Simon Johannes, et al.
Publicado: (2021)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice
por: Li, Rui, et al.
Publicado: (2018)

Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis
por: Lee, Jung Il, et al.
Publicado: (2019)

Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
por: Weinmann, Arndt, et al.
Publicado: (2015)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Evaluation of IL‐6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis
por: Gairing, Simon Johannes, et al.
Publicado: (2022)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
por: Mazo, Daniel FC, et al.
Publicado: (2013)

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
por: Sircana, Antonio, et al.
Publicado: (2019)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
por: Harrison, Stephen A., et al.
Publicado: (2019)

Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis
por: Katayama, Akihiro, et al.
Publicado: (2015)

Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis
por: Kremer, Wolfgang M., et al.
Publicado: (2020)

Risk factors for poorer health literacy in patients with liver cirrhosis
por: Kaps, Leonard, et al.
Publicado: (2021)

A novel diet‐induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis
por: Ejima, Chieko, et al.
Publicado: (2016)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hcnt06gksj7isnvei35b20etod